Brief: Viatris Agrees To Acquire Pacira Biosciences, Advancing Its Innovative Medicines Strategy And Becoming A Leader In Non-Opioid Pain Therapies
08/10/2026 13:10
BRIEF-Viatris Agrees To Acquire Pacira Biosciences, Advancing Its Innovative Medicines Strategy And Becoming A Leader In Non-Opioid Pain Therapies Oct 8 (Reuters) - Pacira BioSciences, Inc. PCRX.O:
VIATRIS AGREES TO ACQUIRE PACIRA BIOSCIENCES, ADVANCING ITS INNOVATIVE MEDICINES STRATEGY AND BECOMING A LEADER IN NON-OPIOID PAIN THERAPIES
VIATRIS - TO BUY PACIRA FOR $36.5 PER SHARE, EQUITY VALUE $1.65 BILLION
VIATRIS - PACIRA TO BECOME WHOLLY OWNED SUBSIDIARY OF VIATRIS; STOCK TO BE DELISTED FROM NASDAQ
VIATRIS - DEAL EXPECTED TO CLOSE BY END OF 2026 AND BE IMMEDIATELY ACCRETIVE
VIATRIS - TO COMMENCE TENDER OFFER FOR PACIRA AT $36.5 PER SHARE
VIATRIS INC.: EXPECT TO FUND TRANSACTION PRIMARILY FROM EXCESS CASH WITH REMAINDER FROM SHORT-TERM BORROWINGS
Source text: ID:nPn9MK1fsa
Further company coverage: PCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal